SG11201809822SA - Atropine-containing aqueous composition - Google Patents
Atropine-containing aqueous compositionInfo
- Publication number
- SG11201809822SA SG11201809822SA SG11201809822SA SG11201809822SA SG11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA
- Authority
- SG
- Singapore
- Prior art keywords
- shi
- buffer
- cho
- international
- takayama
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229930003347 Atropine Natural products 0.000 title abstract 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 title abstract 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 title abstract 2
- 229960000396 atropine Drugs 0.000 title abstract 2
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 abstract 6
- 239000000872 buffer Substances 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000281 trometamol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Photolithography (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111011101111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/204262 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, A61K 31/46 (2006.01) A61K 47/12 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, A61K 9/08 (2006.01) A61K 47/18 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, A61K 47/02 (2006.01) A61K 47/26 (2006.01) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, A61K 47/10 (2006.01) A61K 47/38 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/JP2017/019423 kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 24 May 2017 (24.05.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 10201604200P 25 May 2016 (25.05.2016) SG Published: (71) Applicants: SINGAPORE HEALTH SERVICES PTE — LTD [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer with international search report (Art. 21(3)) Block C, Singapore, 168753 (SG). NANYANG TECH- NOLOGICAL UNIVERSITY [SG/SG]; 50 Nanyang Av- _ enue, Singapore, 639798 (SG). SANTEN PHARMA- CEUTICAL CO., LTD. [JP/JP]; 9-19, Shimoshinjo 3- chome, Higashiyodogawa-ku, Osaka-shi, Osaka, 5338651 — (JP). = Inventors: TAN, Donald; c/o Singapore Eye Research (72) — = Institute, 11 Third Hospital Ave, 168751 (SG). BEUER- MAN, Roger; c/o Singapore Eye Research Institute, 11 _ Third Hospital Ave, 168751 (SG). ASADA, Hiroyuki; c/ = o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP). TAKA- HASHI, Kyohei; c/o SANTEN PHARMACEUTICAL = CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, = 6300101 (JP). SAKANAKA, Koji; c/o SANTEN PHAR- MACEUTICAL CO., LTD., 8916-16, Takayama-cho, Iko- = = ma-shi, Nara, 6300101 (JP). MORIMOTO, Takashi; c/ = o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, = Takayama-cho, Ikoma-shi, Nara, 6300101 (JP). FU- JISAWA, Toyomi; c/o SANTEN PHARMACEUTICAL = CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, = 6300101 (JP). = Agent: SAMEJIMA, Mutsumi et al.; AOYAMA & (74) = — PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, = Kakuda-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (81) — 1-1 N ei iv 0 el (54) Title: ATROPINE-CONTAINING AQUEOUS COMPOSITION IN ,-1 (57) : Disclosed herein is an aqueous composition comprising 0.001 - 0.1 % (w/v) atropine or a salt thereof, a water-soluble 0 polymer, and buffer (I), which is at a pH range of 6 or lower, wherein the buffer (I) is at least one selected from the group consisting of \" a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201604200P | 2016-05-25 | ||
| PCT/JP2017/019423 WO2017204262A1 (en) | 2016-05-25 | 2017-05-24 | Atropine-containing aqueous composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809822SA true SG11201809822SA (en) | 2018-12-28 |
Family
ID=60411416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809822SA SG11201809822SA (en) | 2016-05-25 | 2017-05-24 | Atropine-containing aqueous composition |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20210267885A1 (en) |
| EP (2) | EP3463360B1 (en) |
| JP (4) | JP6590860B2 (en) |
| KR (3) | KR102580933B1 (en) |
| CN (3) | CN109310687B (en) |
| AR (1) | AR108591A1 (en) |
| CA (1) | CA3023149A1 (en) |
| EA (1) | EA201892703A1 (en) |
| ES (1) | ES2929368T3 (en) |
| MY (1) | MY189774A (en) |
| PH (1) | PH12018502421A1 (en) |
| SG (1) | SG11201809822SA (en) |
| TW (3) | TWI791438B (en) |
| UA (1) | UA126195C2 (en) |
| WO (1) | WO2017204262A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| JP2018521000A (en) | 2015-05-29 | 2018-08-02 | シドネキシス，インク． | Pharmaceutical formulation stabilized with D2O |
| SG11201907701YA (en) * | 2017-02-21 | 2019-09-27 | Singapore Health Serv Pte Ltd | Composition and method for preventing or delaying onset of myopia comprising atropine |
| CN110621298B (en) | 2017-05-11 | 2022-12-20 | 维卢玛有限公司 | Atropine pharmaceutical composition |
| CN114557955B (en) * | 2018-09-25 | 2024-06-18 | 沈阳兴齐眼药股份有限公司 | Pharmaceutical composition, preparation method and application thereof |
| EP3701938B8 (en) | 2019-03-01 | 2024-02-21 | Medivis S.R.L. | Ophthalmic formulations based on atropine |
| AU2021320350A1 (en) | 2020-08-04 | 2023-02-09 | Boehringer Ingelheim International Gmbh | Agent for treating myopia, preventing myopia and/or suppressing myopia progression |
| TW202228706A (en) * | 2020-10-14 | 2022-08-01 | 日商參天製藥股份有限公司 | Stable pharmaceutical composition |
| US20220133735A1 (en) | 2020-11-02 | 2022-05-05 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
| WO2022130337A1 (en) * | 2020-12-17 | 2022-06-23 | Sun Pharmaceutical Industries Limited | An aqueous sterile solution of atropine for ophthalmic use |
| EP4088714A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4088713A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| US20230120997A1 (en) * | 2021-10-18 | 2023-04-20 | Ocular Science, Inc. | Compositions and methods for myopia control and orthokeratology lenses treatment |
| CN114129511A (en) * | 2021-12-07 | 2022-03-04 | 河南润弘制药股份有限公司 | Atropine sulfate injection with improved stability |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617508B2 (en) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | Stable aqueous solution containing diphenhydramine |
| US20030096831A1 (en) | 2000-01-18 | 2003-05-22 | Stone Richard A. | Ocular growth and nicotinic antagonists |
| NZ529615A (en) * | 2001-05-25 | 2005-07-29 | Valley Forge Pharmaceuticals | Pirenzepine ophthalmic gel |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| JP2007308398A (en) * | 2006-05-17 | 2007-11-29 | Chang Gung Memorial Hospital | Eye drops and method for producing the same |
| EP2152255A1 (en) * | 2007-05-21 | 2010-02-17 | Neuroptix Corporation | Ophthalmic formulations of amyloid- contrast agents and methods of use thereof |
| WO2012161655A1 (en) * | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US20160009705A1 (en) * | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
| JP2017102939A (en) * | 2016-12-26 | 2017-06-08 | 株式会社プロフィールド | Authoring device, authoring method, and program |
| CN110621298B (en) | 2017-05-11 | 2022-12-20 | 维卢玛有限公司 | Atropine pharmaceutical composition |
-
2017
- 2017-05-24 CA CA3023149A patent/CA3023149A1/en active Pending
- 2017-05-24 TW TW106117194A patent/TWI791438B/en active
- 2017-05-24 TW TW110141612A patent/TWI849355B/en active
- 2017-05-24 AR ARP170101418A patent/AR108591A1/en unknown
- 2017-05-24 KR KR1020227039104A patent/KR102580933B1/en active IP Right Grant
- 2017-05-24 WO PCT/JP2017/019423 patent/WO2017204262A1/en unknown
- 2017-05-24 CN CN201780031738.6A patent/CN109310687B/en active Active
- 2017-05-24 KR KR1020187037233A patent/KR20190013877A/en active Application Filing
- 2017-05-24 UA UAA201812662A patent/UA126195C2/en unknown
- 2017-05-24 TW TW112102321A patent/TW202325296A/en unknown
- 2017-05-24 ES ES17802848T patent/ES2929368T3/en active Active
- 2017-05-24 SG SG11201809822SA patent/SG11201809822SA/en unknown
- 2017-05-24 CN CN202311238651.XA patent/CN117205209A/en active Pending
- 2017-05-24 MY MYPI2018001914A patent/MY189774A/en unknown
- 2017-05-24 EP EP17802848.6A patent/EP3463360B1/en active Active
- 2017-05-24 KR KR1020237031744A patent/KR20230141882A/en not_active Application Discontinuation
- 2017-05-24 JP JP2017102939A patent/JP6590860B2/en active Active
- 2017-05-24 EA EA201892703A patent/EA201892703A1/en unknown
- 2017-05-24 CN CN202311240197.1A patent/CN117205210A/en active Pending
- 2017-05-24 EP EP22189717.6A patent/EP4112055A1/en active Pending
- 2017-05-24 US US16/303,686 patent/US20210267885A1/en not_active Abandoned
-
2018
- 2018-11-16 PH PH12018502421A patent/PH12018502421A1/en unknown
-
2019
- 2019-09-17 JP JP2019168569A patent/JP6886502B2/en active Active
-
2021
- 2021-05-14 JP JP2021082578A patent/JP7224390B2/en active Active
-
2023
- 2023-02-07 JP JP2023016850A patent/JP2023058574A/en active Pending
-
2024
- 2024-05-28 US US18/676,396 patent/US20240307305A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809822SA (en) | Atropine-containing aqueous composition | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201908052PA (en) | Lipid-based nanoparticles with enhanced stability | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201901477PA (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
| SG11201908513RA (en) | Peptides for treatment of diabetes |